Try a new search

Format these results:

Searched for:

person:goodga01

in-biosketch:yes

Total Results:

25


Successful pregnancy with isolated herpes simplex virus encephalitis: case report and review of the literature [Case Report]

Frieden FJ; Ordorica SA; Goodgold AL; Hoskins IA; Silverman F; Young BK
Isolated herpes simplex virus encephalitis in pregnancy is a rare illness with an elusive diagnosis. We describe the second patient to survive this disease and the first to have no sequelae, because of prompt diagnosis and treatment with acyclovir
PMID: 2304724
ISSN: 0029-7844
CID: 18695

Leukoencephalopathy in normal and pathologic aging: 2. MRI of brain lucencies

George AE; de Leon MJ; Kalnin A; Rosner L; Goodgold A; Chase N
A pilot study was performed to test the ability of MR to evaluate the brain lucencies shown by CT in Alzheimer disease patients and in normal control subjects. Eight patients with presumed Alzheimer disease and 47 normal controls, 12 over the age of 45 years and 35 under age 45, were studied. Each group included subjects with and without CT evidence of leukoencephalopathy. Inversion recovery, saturation recovery, and spin-echo scans were obtained using a 0.3-T permanent magnet prototype unit. Results indicated that MR was more sensitive than CT to parenchymal disease. Seven of the eight patients with Alzheimer disease showed patches of increased signal intensity on SE scans; only three had lucencies on their CT studies. None of the normal subjects under the age of 45 showed periventricular patches of increased SE signal intensity. T2-weighted SE imaging was performed in nine of the 12 normal subjects over 45 years old. Eight of the nine demonstrated periventricular patches of increased SE signal intensity. Faint CT lucencies were present in only one of these. The configuration of the patches of increased signal intensity was similar for both the normal and Alzheimer groups, but the extent of white-matter involvement was greater in the Alzheimer group.
PMID: 3088934
ISSN: 0195-6108
CID: 9476

Tardive dyskinesia-like disorder due to basal ganglia infarction [Letter]

Serby, M; Goodgold, A
PMID: 3700700
ISSN: 0271-0749
CID: 3692822

MAGNETIC-RESONANCE AND POSITRON EMISSION TOMOGRAPHY EVALUATIONS OF HYDROCEPHALUS [Meeting Abstract]

GEORGE, AE; DELEON, M; KALNIN, A; ROSNER, L; MILLER, J; COOPER, P; FOO, S; CHRISTMAN, D; GOODGOLD, A; WOLF, A; CHASE, N
ISI:A1984TG20900072
ISSN: 0195-6108
CID: 40913

LEUKOENCEPHALOPATHY OF AGING .2. CT CLINICAL MRI STUDY OF BRAIN LUCENCIES [Meeting Abstract]

GEORGE, AE; DELEON, M; KALNIN, A; ROSNER, L; GOODGOLD, A; CHASE, N
ISI:A1984TG20900103
ISSN: 0195-6108
CID: 40915

Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor

Lieberman AN; Gopinathan G; Neophytides A; Hiesiger E; Nelson J; Walker R; Goodgold A
PMID: 6422358
ISSN: 0028-7628
CID: 61611

Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease

Lieberman, A N; Neophytides, A; Leibowitz, M; Gopinathan, G; Pact, V; Walker, R; Goodgold, A; Goldstein, M
Treatment with pergolide was compared with bromocriptine in 25 patients, all of whom were also receiving levodopa and in all of whom the response to levodopa had diminished. All 25 patients had 'on-off' phenomena. At the time bromocriptine was added to levodopa, the mean age of the patients was 61.8 years, mean duration of disease was 9.0 years, and mean duration of levodopa treatment was 6.1 years. For the group as a whole, disability as determined in the 'on' period decreased by 36%, from 28.7 to 18.5; and 11 patients improved at least one stage. Disability as determined in the 'off' period decreased by 25%, from 59.5 to 44.4. The number of hours in which patients were 'on' increased by 62%, from 7.1 to 11.5. All of these changes were significant (p less than or equal to 0.05). Bromocriptine had to be discontinued in nine patients (eight because of mental changes). In the remaining 16 patients, bromocriptine was eventually discontinued because of diminishing efficacy. Mean dose of bromocriptine was 50 mg (range, 10-100 mg), and mean duration of treatment was 23 months (range, 2-65 months). At the time of their treatment with pergolide, the patients were older, 65.5 years, had the disease longer, 12.7 years, and were more disabled. Nonetheless, for the group as a whole, disability score as determined in the 'on' period decreased significantly by 40%, from 43.5 to 26.3, and 14 patients improved at least one stage. Disability as determined in the 'off' period decreased significantly by 21%, from 69.0 to 54.8. The number of hours in which patients were 'on' increased significantly by 224%, from 3.4 to 11.0 hr. The mean dose of pergolide was 2.1 mg (range, 0.1-10.0 mg), and the mean duration of treatment was 6.2 months (range, 0.5-20 months). Pergolide was discontinued in eight patients: three because of asymptomatic tachyarrhythmias of unknown clinical significance (detected only by Holter monitoring); two because of orthostatic hypotension; and two because of mental changes. Although pergolide appears to be more potent than bromocriptine because of its greater effect in a larger number of patients at a more advanced stage of their disease, both drugs are useful, and both enhance our ability to manage patients with PD
PMID: 6858782
ISSN: 0091-3952
CID: 122212

SEQUELAE OF NITROUS-OXIDE ABUSE

Greenblum, DN; Serby, M; Goodgold, AL
ISI:A1982NG12100010
ISSN: 0033-3182
CID: 30325

Sequelae of nitrous oxide abuse

Greenblum, DN; Serby, M; Goodgold, AL
SCOPUS:85025775568
ISSN: 0033-3182
CID: 2653222

Use of lisuride in advanced Parkinson's disease. Potent dopamine and serotonin agonist

Lieberman, A N; Goldstein, M; Neophytides, A; Leibowitz, M; Gopinathan, G; Goodgold, A; Pact, V; Walker, R
PMID: 6949052
ISSN: 0028-7628
CID: 122220